Vaxcyte, Inc. Cash Flow Statement
PCVX / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Vaxcyte, Inc. used $656M in operating cash flow and negative free cash flow of $669M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$766.6M | -$463.9M | -$402.3M | -$223.5M | -$100.1M | -$89.2M | -$50.3M | -$29.5M |
| Depreciation & Amortization | $16.4M | $7.0M | $3.2M | $2.8M | $1.8M | $1.4M | $1.2M | $1.0M |
| Operating Cash Flow | -$655.6M | -$452.6M | -$296.8M | -$170.6M | -$121.4M | -$46.6M | -$47.1M | -$30.5M |
| Capital Expenditures | $13.7M | $22.4M | $16.1M | $5.8M | $6.6M | $1.2M | $1.2M | $1.8M |
| Free Cash Flow | -$669.3M | -$475.1M | -$312.9M | -$176.4M | -$127.9M | -$47.8M | -$48.3M | -$32.2M |